Johnson & Johnson is set to report earnings before the bell — here's what the Street expects

Johnson & Johnson reports earnings Tuesday before the bell.

Here's what Wall Street expects, based on a survey of analysts by Refinitiv:

• Earnings per share: $2.03
• Revenue: $20.05 billion

Pharmaceuticals, specifically cancer drugs, have fueled J&J's growth while its consumer and medical device businesses have lagged. J&J recently completed the divestiture of its LifeScan diabetes business to Platinum Equity for $2.1 billion. It also relaunched its iconic baby care line in August after facing a 20 percent sales decline since 2011.

Earlier this month, J&J inked an agreement with Arrowhead Pharmaceuticals to develop its gene-silencing Hepatitis B treatment and take a minority stake in the company. The deal could potentially be worth more than $3.7 billion.

Let's block ads! (Why?)

from Top News & Analysis https://ift.tt/2Cl1YWH
via IFTTT